HSCI experts have reported on the DNA chip Etnogen

In June 2013 Human Stem Cell Institute (JSC "HSCI) took part in the European Conference of Human Genetics (European Human Genetics Conference-2013). HSCI experts presented to the participants of the conference report "Predictive genetic testing using DNA microarray technology — a promising preventive approach to medical practice", which described the developed in HSCI DNA chip "Etnogen" for the diagnosis of hereditary diseases, the press service of the HSCI.

Chip "Etnogen" is fundamentally different from those already on the market diagnostic systems in that it focuses on identifying genetic diseases specific to the peoples living on the

Continue reading HSCI experts have reported on the DNA chip Etnogen

HSCI experts have reported on the DNA chip Etnogen

In June 2013 Human Stem Cell Institute (JSC "HSCI) took part in the European Conference of Human Genetics (European Human Genetics Conference-2013). HSCI experts presented to the participants of the conference report "Predictive genetic testing using DNA microarray technology — a promising preventive approach to medical practice", which described the developed in HSCI DNA chip "Etnogen" for the diagnosis of hereditary diseases, the press service of the HSCI.

Chip "Etnogen" is fundamentally different from those already on the market diagnostic systems in that it focuses on identifying genetic diseases specific to the peoples living on the

Continue reading HSCI experts have reported on the DNA chip Etnogen

In Moscow, opened Russia’s first specialized center for the development of cellular technology

photo — Human Stem Cell Institute

June 11, 2013 the grand opening of the laboratory and production complex Center for Genetics and Regenerative Medicine Institute of Human Stem Cells "TSGRM HSCI." His creation — is a strategically important step not only for the HSCI, but also for the industry as a whole. In addition to the products and services HSCI, the new complex is designed for contract manufacturing of biomedical cell products and preparations of other Russian and foreign software companies and is intended to make it more affordable and effective pre-clinical and clinical trials of cell preparations,

Continue reading In Moscow, opened Russia’s first specialized center for the development of cellular technology

Russian Neovaskulgen innovative drug in the U.S.

The American Society of Gene and Cell Therapy (ASGCT) invited representatives Institute of Human Stem Cells (HSCI) to speak at the 16th Annual International Conference in Salt Lake City and talk about the third world gennoterapevticheskom preparation Neovaskulgen, developed in the HSCI.

ASGCT Conference is an important event in the field of gene and cell therapy, highlights the advanced technology and advances represents a pioneering clinical trial results. This year, the 4-day event (15-18 May), attended by specialists Bole 1700. With plenary lectures were given by Nobel laureates Mario Capecchi and David Baltimore.

The specialists

Continue reading Russian Neovaskulgen innovative drug in the U.S.

Innovative product Neovaskulgen gaining market

Moscow — March 26, 2013. Human Stem Cell Institute— JSC "HSCI" (MICEX: ISKJ) announces the signing of an agreement for the supply of JSC "PharmFirma" Sotex "innovative drug Neovaskulgen ®, developed by HSCI and for the treatment of lower limb ischemia.

"PharmFirma Sotex" which is a group of companies "Protek", is one of the largest players on the pharmaceutical market in Russia and has a unique experience to the market launch of innovative medicines.

Supply agreement has been signed by companies March 25, 2013 for a term of three years with the possibility of

Continue reading Innovative product Neovaskulgen gaining market

New product team leading Russian specialists from the Institute of Human Stem Cells.

The team of leading Russian experts in the field of biology and genetics of Human Stem Cells Institute (HSCI) introduced a product by which the human body are formed and grow new clean vascular network. Neovaskulgen — substance stored in dry form. For intramuscular injection, it is necessary to dilute aqueous solution. The course of treatment — two injections with an interval of fourteen days. According to the Director of Science HSCI Roman Deev, in clinical studies of patients with positive results were evident in a couple of weeks after the second injection.

The principle of operation of genetic

Continue reading New product team leading Russian specialists from the Institute of Human Stem Cells.

The invention of scientists from HSCI produces various tissues of the human body

Moscow, July 20, 2012. Research Unit Institute of Human Stem Cells (HSCI), Laboratory of Cell Technology, received a diploma in the nomination RosPatent 100 best inventions of 2011 Russia (Russian Federation Patent number 2,384,618 "Method of fibroblast-like cells from umbilical cord baby"). The grand award ceremony was held on 28 June 2012 at the meeting of the Scientific and Technical Council of Rospatent and FIPS of the Day of the inventor and innovator.

Patent "Method of fibroblast-like cells from umbilical cord baby" in the State Register of Inventions of Russia March 20, 2010. The developed method enables the highlight

Continue reading The invention of scientists from HSCI produces various tissues of the human body

Put into production medication to grow new blood vessels to replace the old

New veins instead of the old grow injection

"Human Stem Cell Institute" presented a drug that promotes the cultivation of new blood vessels instead of deformed

Russian biotech company "Human Stem Cell Institute" (HSCI) launched the world’s first mass production in preparation to grow new blood vessels to replace the old scored cholesteric plaques. The medicine is called "Neovaskulgen", it makes the injection capillary network of randomly spread. The developers say that this method of treatment of ischemia — the only alternative to conducting operations in advanced cases of the disease.

— We did a pilot

Continue reading Put into production medication to grow new blood vessels to replace the old

Russian Neovaskulgen innovative drug in the U.S.

The American Society of Gene and Cell Therapy (ASGCT) invited representatives Institute of Human Stem Cells (HSCI) to speak at the 16th Annual International Conference in Salt Lake City and talk about the third world gennoterapevticheskom preparation Neovaskulgen, developed in the HSCI.

ASGCT Conference is an important event in the field of gene and cell therapy, highlights the advanced technology and advances represents a pioneering clinical trial results. This year, the 4-day event (15-18 May), attended by specialists Bole 1700. With plenary lectures were given by Nobel laureates Mario Capecchi and David Baltimore.

The specialists

Continue reading Russian Neovaskulgen innovative drug in the U.S.

New product team leading Russian specialists from the Institute of Human Stem Cells.

The team of leading Russian experts in the field of biology and genetics of Human Stem Cells Institute (HSCI) introduced a product by which the human body are formed and grow new clean vascular network. Neovaskulgen — substance stored in dry form. For intramuscular injection, it is necessary to dilute aqueous solution. The course of treatment — two injections with an interval of fourteen days. According to the Director of Science HSCI Roman Deev, in clinical studies of patients with positive results were evident in a couple of weeks after the second injection.

The principle of operation of

Continue reading New product team leading Russian specialists from the Institute of Human Stem Cells.

SQL - 17 | 0,551 сек. | 7.73 МБ